Literature DB >> 31956634

Empowering Hypertensive Patients in South Africa to Improve Their Disease Management: A Pharmacist-Led Intervention.

Enos M Rampamba1, Johanna C Meyer1, Elvera A Helberg1, Brian Godman1,2,3,4.   

Abstract

OBJECTIVE: Uncontrolled hypertension negatively impacts on mortality. This study aimed to evaluate the impact of a pharmacist-led patient counseling and education model to empower hypertensive patients on chronic medication.
METHODS: This was an operational research project with a quasi-experimental design including an intervention group (55 patients) and a control group (31 patients) of chronic hypertensive patients. The data were collected with interview-administered questionnaires, and were analyzed using SAS® version 9.4. Pharmacist interventions included an educational diary on hypertension management and patient counseling.
FINDINGS: A 34.7% improvement was observed in patients' understanding of what normal blood pressure (BP) is in the intervention group compared to the control group (P < 0.001), whereas a 9.1% improvement was also observed in the intervention group in their knowledge about the fact that systolic BP and diastolic BP are both important in controlling hypertension, with no change in the control group. After the intervention, 40.0% of patients in the intervention group versus 17.9% in the control group had adequate knowledge (≥75% correct answers) about hypertension and its management. Pharmacist interventions were well received by the majority of patients (>90%).
CONCLUSION: A pharmacist-led patient counseling and education model can help improve patients' hypertension knowledge and BP control. These should increasingly become routine, aiming to improve chronic disease management. Copyright:
© 2019 Journal of Research in Pharmacy Practice.

Entities:  

Keywords:  Chronic hypertension; South Africa; empowerment; patient knowledge; pharmacist intervention

Year:  2019        PMID: 31956634      PMCID: PMC6952763          DOI: 10.4103/jrpp.JRPP_18_74

Source DB:  PubMed          Journal:  J Res Pharm Pract        ISSN: 2279-042X


INTRODUCTION

Prevalence rates of hypertension are generally high among African countries.[12] South Africa has one of the highest prevalence rates of hypertension worldwide reaching 77.9% in people aged above 50 years,[1] with high rates generally common among African countries.[12] Hypertension is the fastest growing noncommunicable disease (NCD) in South Africa, with hypertension being the major cause of death among patients with NCDs.[3] Overall, hypertension accounts for most deaths due to stroke and heart attack across Africa.[124] Primary health-care (PHC) facilities are the foundation of the South African health-care system and where the majority of hypertensive patients are managed; however, there are concerns with blood pressure (BP) control.[56] Hypertensive patients should receive counseling and education when visiting PHC facilities, as well as be satisfied with their treatment to reduce future morbidity and mortality.[3789] Written hypertension information leaflets or booklets are effective with improving knowledge about hypertension and subsequent medicine taking,[1011] with written information serving as a continuous, reliable source about the disease and its treatment.[811] Patients should receive such information during counseling, which currently does not always happen in South Africa.[6] Such booklets provide a platform for both pharmacists and patients to develop hypertension care plans, empowering patients to become more personally involved with their treatment.[1011] This is important in South Africa in view of concerns with BP control,[612] and following the implementation of the Central Chronic Medicines Dispensing and Distribution (CCMDD) program to enhance access to medicines for patients in the public system and to aid adherence.[12] Within the CCMDD program, medicines are packaged and distributed free of charge to patients’ nearest pick-up point.[12] Consequently, the main aim of this study was to evaluate the impact of a pharmacist-driven patient counseling and education model in South Africa in PHC facilities to empower hypertensive patients with knowledge. The specific objectives were to determine hypertensive patients’ knowledge of their disease and its management, BP control, and self-reported adherence to treatment before and after the implementation of the pharmacist intervention, and subsequently to determine hypertensive patients’ satisfaction with pharmacist interventions to inform future initiatives.

METHODS

Operational research project with a quasi-experimental design among patients with hypertension attending PHC facilities in Vhembe District of Limpopo Province.[13] The original design used stratified random sampling to allocate 60 out of 120 facilities to the intervention and control groups. The intention was to initially approach 600 patients based on an estimated 50% drop-out rate following statistical advice. Stratification was undertaken according to the municipality, type, and size to ensure each group was balanced and comparable. However, challenges such as community strikes and riots meant that only 50 PHC facilities eventually took part, 25 in each group. The data were collected on the scheduled clinic return-date over 6 months by trained pharmacists, with a 4-month interval for each patient between baseline and post-intervention visits. Randomization was used to select up to 15 hypertensive patients per facility, based on the availability and willingness of patients who met the inclusion criteria on the day of data collection, which was principally adults on chronic antihypertensive treatment for more than 6 months and without organ damage. The first random patient was approached, enrolled if willing, and when completed, the next available patient was approached. This process continued resulting in 253 patients being eventually enrolled in the study: 138 in the intervention group and 115 in the control group. Patients in both groups received usual care and were requested to collect their medicines monthly. The intervention group was exposed to a pharmacist intervention at enrollment with the control group introduced to the intervention at the end. The pharmacist intervention included a hypertension information diary for daily use, with 15–30 minutes of patient counseling and education about hypertension and its management, and the correct use of the diary. The diary also had space for patients to record their BP, lifestyle changes, and any adverse effects. The counseling was performed on the first visit immediately after the questionnaire was administered. A structured questionnaire was developed based on previously published studies,[141516] translated into local languages, and piloted among 22 hypertensive patients from another district in the Province with a similar socioeconomic status as the study facilities. This assisted in simplifying the language used, helping to avoid different interpretations. Training of all data collectors and cross-checking of entered data took place to ensure the validity and reliability of the data. The validity of the results was supported by the study design in which the control group was exposed to the same conditions as the intervention group, except for the patient counseling and education model (intervention). Demographic data included educational status with patients with formal education (completed at least primary school and up to secondary school and tertiary education) being classified as educated.[17] Patients’ knowledge of hypertension and its management, self-reported adherence, and lifestyle habits were assessed for both groups. Patients’ knowledge testing questions were classified into four groups including (1) understanding and knowledge of hypertension, (2) knowledge on BP measurement and readings, (3) knowledge about medication and lifestyle, and (4) knowledge of the dangers of uncontrolled high BP. Adequate knowledge about hypertension was considered as 75% of answers provided correctly.[18] Patients rated their adherence to treatment using six predefined categorized responses, i.e., excellent, very good, good, fair, poor, and very poor, which have been previously used in adherence studies.[919] Previous studies had revealed that participants felt more comfortable and confident with words compared to numbers for rating adherence, and a 30-day recall performed better compared to a 3-day or 7-day recall.[1920] Patients’ BP as taken by the nurse at the facility on the day of data collection was recorded from their clinic record card. BP recordings between enrollment and study end were collected retrospectively. At the study end, patients with uncontrolled BP were counseled on medication adherence and referred to the medical practitioner to assess their treatment regimen and discuss future care. Data were captured electronically on Microsoft Excel™. Responses to open-ended questions were typed up manually and grouped into categories. Data were analyzed using SAS®2018 (SAS Institute Inc, Carey, North Caroline, USA) version 9.4. Baseline characteristics between the intervention group and the control group were compared using the Fisher's exact test. Positive changes in hypertension management knowledge from baseline to the final post-intervention visit in the intervention and control groups were determined using the same test. A two-sided P ≤ 0.05 indicated statistical significance. The primary outcome was the proportion of patients with adequate knowledge of the management of hypertension after the pharmacist intervention. The secondary outcomes included (i) positive changes for individual variables from baseline to post-intervention, (ii) decrease in systolic and diastolic BP, (iii) proportion of patients with controlled BP, and (iv) the proportion of patients being satisfied with the pharmacist intervention. The pharmacist intervention was considered acceptable if there was at least 80% agreement or satisfaction among all respondents. Ethical clearance for the study was obtained from the Medunsa Research Ethics Committee of the University of Limpopo, currently Sefako Makgatho Health Sciences University (MRECH 27/2014: PG). Permission to conduct the study was obtained from the Limpopo Department of Health and the Vhembe District Executive Manager. All patients provided written informed consent to participate.

RESULTS

Losses to follow-up resulted in a final sample of 55 patients in the intervention group and 31 in the control group. These differences reflect that only patients with baseline and post-intervention data were included in the analysis. Table 1 shows that females predominated with no differences in baseline characteristics between the groups. Comorbidities were present in 33.3% of the control group and 49.1% among intervention patients, of which diabetes was most common. Other comorbidities included shortness of breath, ulcers, heart problems, and arthritis.
Table 1

Comparison of baseline characteristics between the intervention group and the control group

Patient characteristicsIntervention group (n=55)Control group (n=31)P*
Gender, n (%)0.337
 Female49 (89.1)25 (80.7)
 Male6 (10.9)6 (19.4)
Age (years)
 Mean±SD62.1±11.265.9±12.00.145
 Median (Q1-Q3)63 (53-67)65 (59-76)-
Marital status, n (%)0.755
 Married27 (49.1)18 (58.1)
 Divorced3 (5.5)0
 Never married9 (16.4)4 (12.9)
 Separated1 (1.8)0
 Widowed15 (27.2)9 (29.0)
Education†, n (%)1.000
 Educated23 (41.8)13 (41.9)
 Uneducated32 (58.2)18 (58.1)
Comorbidities, n (%)0.178
 Comorbidity27 (49.1)10 (33.3)
 No comorbidity28 (50.9)20 (66.7)
 Diabetes as comorbidity16 (29.6)5 (16.7)0.292
Duration of treatment (years), n (%)0.801
 1-514 (25.4)9 (29.1)
 >541 (74.6)22 (70.9)
BP, mean±SD
 Systolic BP138.6±21.8138.7±21.60.990
 Diastolic BP78.9±9.682.6±11.10.118
Weight and BMI, mean±SD
 Weight (kg)76.7±14.576.6±14.20.962
 BMI30.9±6.8 (n=32)30±4.8 (n=10)0.673

*Fisher’s exact test; †Completed at least primary education. SD=Standard deviation, Q1=Quartile 1, Q3=Quartile 3, BMI=Body mass index, BP=Blood pressure

Comparison of baseline characteristics between the intervention group and the control group *Fisher’s exact test; †Completed at least primary education. SD=Standard deviation, Q1=Quartile 1, Q3=Quartile 3, BMI=Body mass index, BP=Blood pressure Before the intervention, approximately 90% of the patients in both groups did not have adequate knowledge about hypertension management. This changed with 40.0% of the patients in the intervention group and 17.9% in the control group having sufficient knowledge, although this was not statistically significant. Table 2 shows the positive changes for each knowledge question and self-reported adherence from baseline to post-intervention visits for both groups. Although a number of positive changes were observed after the pharmacist intervention, the only statistically significant (P < 0.001) improvement in the intervention group was in the understanding of normal BP.
Table 2

Positive changes in hypertension management knowledge from baseline to the final post-intervention visit in intervention and control groups

StatementPositive changes from baseline to post-intervention

Intervention groupControl group

Number/sample sizePercentageNumber/sample sizePercentage
Understanding and knowledge of hypertension
 Definition of hypertension20/4940.814/2948.3
 Normal BP17/4934.70/250.0*
 Causes of high BP13/5324.56/2821.4
 Benefits of taking medicines for high BP correctly9/4520.04/2714.8
Knowledge of BP measurement and readings
 Importance of BP numbers5/559.10/290.0
 Meaning of the reported BP numbers6/5510.91/283.57
 BP readings written down on paper13/5523.63/2910.3
Knowledge about medication and lifestyle
 Taking hypertension medicines as prescribed is necessary and important0/550.00/310.0
 Exercise is important to control high BP1/492.00/270.0
 Smoking is dangerous to hypertensive patients2/494.11/293.5
 Alcohol is dangerous to hypertensive patients2/504.02/296.9
 Can do something to lower high BP16/5330.29/3030.0
Knowledge about hypertension complications and its dangers
 Dangers of uncontrolled high BP6/5510.92/287.1
 Self-reported medication adherence6/5510.912/3138.7#

*Significant improvement in the study group, #Significant improvement in the control group. BP=Blood pressure

Positive changes in hypertension management knowledge from baseline to the final post-intervention visit in intervention and control groups *Significant improvement in the study group, #Significant improvement in the control group. BP=Blood pressure More of the patients in the intervention group (19.5%) than in the control group (10.7%) who had uncontrolled BP at baseline had controlled BP post-intervention. However, this did not reach statistical significance. The majority (≥89.8%) of the patients in the intervention group expressed their satisfaction with various aspects of the counseling by pharmacists [Figure 1].
Figure 1

Patient satisfaction with pharmacist counseling and education (intervention group)

Patient satisfaction with pharmacist counseling and education (intervention group) Most (97.7%) patients found the dairies easy to use, motivated them to change their lifestyle, and become more health wise. Similarly, 90.9% stated that the study aided them to remember their medicines and clinic appointments. Overall, 90% of the patients who were exposed to the diary expressed their satisfaction with its content and use. Only a minority found them time-consuming (43.2%). Family members also supported patients in helping them to improve their BP control. This included helping those patients who found it difficult to read themselves from the diaries, further assisted by trust in the information provided in the diary, which was typically shared with family members and friends. Some patients however preferred face-to-face counseling sessions with the pharmacist instead of an information booklet, which needs to be factored into any future program.

DISCUSSION

It was encouraging to see pharmacist-led interventions being well received, similar to Dawes et al. in which a patient booklet was well received.[10] Some patients subsequently requested that this pharmacist-led intervention should be routinely implemented in PHC facilities throughout South Africa to assist with reducing BP. The strengthening of patient–pharmacist relationships could help improve satisfaction with healthcare services generally and treatment outcomes in the future. There was also an indication that written information can improve patients’ knowledge of hypertension with patients sharing their information with family and friends. Furthermore, those experiencing reading difficulties were assisted by family members. These factors should be considered as South Africa instigates measures to improve adherence to medicines in patients with NCDs including the CCMDD program.[12] The greater change in patients’ knowledge of what hypertension is in the control group may be due to patient curiosity after being asked what hypertension is during enrollment versus the knowledge provided to the intervention group. In addition, this knowledge was only offered once in the intervention group at the start, and forgetfulness could be an issue in the intervention group.[11] However, to balance this, there was a significant improvement in patients’ knowledge of what is normal BP in the intervention group Table 2, similar to other studies.[101121] A positive change in the intervention group in knowing that both systolic and diastolic BP readings are important for controlling hypertension is encouraging, as this is likely to improve patients’ involvement in the management of their disease.[22] A positive change was also seen in BP control, with a greater reduction in the intervention group [Table 3]; however, this did not reach statistical significance. This may be due to high dropout rates as significant changes have been seen in BP control in patients with hypertension after pharmacist interventions in other studies.[21]
Table 3

Changes in mean systolic and diastolic blood pressure from baseline to post-intervention for the intervention and control groups

Mean blood pressure; mmHg (SD)

nIntervention groupnControl group
Mean systolic BP
 Baseline52138.6 (21.8)31138 (21.6)
 Post-intervention55135.7 (22.0)28138.4 (20.1)
 Change: Baseline to post-intervention*40−4.6280.75
P0.1220.869
Mean diastolic BP
 Baseline5278.9 (9.6)3182.6 (11.1)
 Post-intervention5576.6 (11.3)2879.1 (12.9)
 Change: Baseline to post-intervention*40−2.528−1.46
P400.272280.496
Intervention group versus control group*
P400.584280.379

*Change was calculated only in patients with baseline and post-intervention data. SD=Standard deviation, BP=Blood pressure

Changes in mean systolic and diastolic blood pressure from baseline to post-intervention for the intervention and control groups *Change was calculated only in patients with baseline and post-intervention data. SD=Standard deviation, BP=Blood pressure A negative finding was that self-reported medication adherence significantly improved in the control group compared to the intervention group [Table 2]. This may be due to improved relationships between patients and pharmacists resulting in honest answers in the intervention group.[23] Consequently, low adherence in the intervention group may be a better representation of actual practice,[2324] with previous studies showing that knowledge is the most significant factor in medication adherence among hypertensive patients.[25] With improved medicines accessibility through the CCMDD program in South Africa,[12] it will be essential to strengthen patients’ involvement in their treatment. Such programs should also include potential ways of addressing illiteracy among patients where this is a concern to help complete hypertension diaries. The main limitation was the high drop-out rate due to the inaccessibility of some of the facilities. Cross-contamination between the intervention and control groups cannot be excluded. We have also not been able to compare our findings with others as we are unaware of studies that have jointly assessed the combination of patient diaries and counseling. Despite these limitations, we believe our findings give a basis for improving the future care of hypertensive patients in PHC facilities in South Africa. Encouragingly, patients in PHC facilities in South Africa were highly satisfied with the pharmacist intervention, laying a strong foundation for improving collaboration in the future. Consequently, it is recommended that this intervention model be further developed and tested, with a greater focus on lifestyle changes and clinical outcomes. Pharmacists should also help routinely instigate and review patient diaries to help improve future control of BP.

AUTHORS’ CONTRIBUTION

Enos M. Rampamba, Johanna C. Meyer, and Elvera A. Helberg devised the concept for the study, developed the questionnaire, and educated the pharmacists taking part. Enos M. Rampamba and Johanna C. Meyer undertook the initial analysis. Enos M. Rampamba, Johanna C. Meyer, and Brian Godman undertook the first draft of the paper, with all authors involved in the subsequent revisions.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  17 in total

1.  Knowledge of hypertension and its management among hypertensive patients on chronic medicines at primary health care public sector facilities in South Africa; findings and implications.

Authors:  Enos M Rampamba; Johanna C Meyer; Elvera Helberg; Brian Godman
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-07-25

Review 2.  Operational research in low-income countries: what, why, and how?

Authors:  Rony Zachariah; Anthony D Harries; Nobukatsu Ishikawa; Hans L Rieder; Karen Bissell; Kayla Laserson; Moses Massaquoi; Micheal Van Herp; Tony Reid
Journal:  Lancet Infect Dis       Date:  2009-11       Impact factor: 25.071

3.  Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases.

Authors:  Vilma E Irazola; Laura Gutierrez; Gerald Bloomfield; Rodrigo M Carrillo-Larco; Prabhakaran Dorairaj; Thomas Gaziano; Naomi S Levitt; J Jaime Miranda; Antonio Bernabe Ortiz; Krisela Steyn; Yangfeng Wu; Denis Xavier; Lijing L Yan; Jiang He; Adolfo Rubinstein
Journal:  Glob Heart       Date:  2016-03

4.  Hypertension knowledge, awareness, and attitudes in a hypertensive population.

Authors:  Susan A Oliveria; Roland S Chen; Bruce D McCarthy; Catherine C Davis; Martha N Hill
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

5.  Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications.

Authors:  Jennifer M Mbui; Margaret N Oluka; Eric M Guantai; Kipruto A Sinei; Loice Achieng; Amanj Baker; Mary Jande; Amos Massele; Brian Godman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-05       Impact factor: 5.045

Review 6.  Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects.

Authors:  J Ø Nielsen; A D Shrestha; D Neupane; P Kallestrup
Journal:  J Hum Hypertens       Date:  2016-06-16       Impact factor: 3.012

7.  Patient related factors for optimal blood pressure control in patients with hypertension.

Authors:  Wang Yi-Bing; Kong De-Gui; Ma Long-Le; Wang Le-Xin
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

8.  Cognitive and field testing of a new set of medication adherence self-report items for HIV care.

Authors:  Ira B Wilson; Floyd J Fowler; Carol A Cosenza; Joanne Michaud; Judy Bentkover; Aadia Rana; Laura Kogelman; William H Rogers
Journal:  AIDS Behav       Date:  2014-12

9.  Relationship between patients' knowledge and medication adherence among patients with hypertension.

Authors:  Beata Jankowska-Polańska; Izabella Uchmanowicz; Krzysztof Dudek; Grzegorz Mazur
Journal:  Patient Prefer Adherence       Date:  2016-12-07       Impact factor: 2.711

10.  Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study.

Authors:  Johanna C Meyer; Natalie Schellack; Jacobus Stokes; Ruth Lancaster; Helecine Zeeman; Douglas Defty; Brian Godman; Gavin Steel
Journal:  Front Pharmacol       Date:  2017-11-09       Impact factor: 5.810

View more
  7 in total

1.  Perceptions, Expectations, and Experience of Physicians About Pharmacists and Pharmaceutical Care Services in Pakistan: Findings and Implications.

Authors:  Khezar Hayat; Zia Ul Mustafa; Brain Godman; Muhammad Arshed; Jiaxing Zhang; Faiz Ullah Khan; Fahad Saleem; Krizzia Lambojon; Pengchao Li; Zhitong Feng; Yu Fang
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

2.  Suboptimal control for patients with type 2 diabetes in the Central Chronic Medicine Dispensing programme in South Africa.

Authors:  Patrick Ngassa Piotie; Elizabeth M Webb; Paul Rheeder
Journal:  Afr J Prim Health Care Fam Med       Date:  2021-03-24

3.  Medicines Availability among Hypertensive Patients in Primary Health Care Facilities in a Rural Province in South Africa: Findings and Implications.

Authors:  Enos M Rampamba; Johanna C Meyer; Elvera Helberg; Brian Godman
Journal:  J Res Pharm Pract       Date:  2021-01-11

4.  Health promotion interventions for the control of hypertension in Africa, a systematic scoping review from 2011 to 2021.

Authors:  Jinhee Shin; Kennedy Diema Konlan; Eugenia Mensah
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

5.  The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.

Authors:  Brian Godman; Mainul Haque; Trudy Leong; Eleonora Allocati; Santosh Kumar; Salequl Islam; Jaykaran Charan; Farhana Akter; Amanj Kurdi; Carlos Vassalo; Muhammed Abu Bakar; Sagir Abdur Rahim; Nusrat Sultana; Farzana Deeba; M A Halim Khan; A B M Muksudul Alam; Iffat Jahan; Zubair Mahmood Kamal; Humaira Hasin; Shamsun Nahar; Monami Haque; Siddhartha Dutta; Jha Pallavi Abhayanand; Rimple Jeet Kaur; Godfrey Mutashambara Rwegerera; Renata Cristina Rezende Macedo do Nascimento; Isabella Piassi Dias Godói; Mohammed Irfan; Adefolarin A Amu; Patrick Matowa; Joseph Acolatse; Robert Incoom; Israel Abebrese Sefah; Jitendra Acharya; Sylvia Opanga; Lisper Wangeci Njeri; David Kimonge; Hye-Young Kwon; SeungJin Bae; Karen Koh Pek Khuan; Abdullahi Rabiu Abubakar; Ibrahim Haruna Sani; Tanveer Ahmed Khan; Shahzad Hussain; Zikria Saleem; Oliver Ombeva Malande; Thereza Piloya-Were; Rosana Gambogi; Carla Hernandez Ortiz; Luke Alutuli; Aubrey Chichonyi Kalungia; Iris Hoxha; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Ott Laius; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuoliene; Jolanta Gulbinovič; Magdalene Wladysiuk; Jakub Rutkowski; Ileana Mardare; Jurij Fürst; Stuart McTaggart; Sean MacBride-Stewart; Caridad Pontes; Corinne Zara; Eunice Twumwaa Tagoe; Rita Banzi; Janney Wale; Mihajlo Jakovljevic
Journal:  Front Public Health       Date:  2021-06-24

6.  Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district.

Authors:  H M Haines; J C Meyer; R S Summers; B B Godman
Journal:  Eur J Clin Pharmacol       Date:  2020-04-15       Impact factor: 2.953

Review 7.  Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future.

Authors:  Brian Godman; Debashis Basu; Yogan Pillay; Julius C Mwita; Godfrey Mutashambara Rwegerera; Bene D Anand Paramadhas; Celda Tiroyakgosi; Patrick Mbah Okwen; Loveline Lum Niba; Justice Nonvignon; Israel Sefah; Margaret Oluka; Anastasia N Guantai; Dan Kibuule; Francis Kalemeera; Mwangana Mubita; Joseph Fadare; Olayinka O Ogunleye; Larry A Distiller; Enos M Rampamba; Jeffrey Wing; Debjani Mueller; Abubakr Alfadl; Adefolarin A Amu; Zinhle Matsebula; Aubrey Kalungia; Trust Zaranyika; Nyasha Masuka; Janney Wale; Ruaraidh Hill; Amanj Kurdi; Angela Timoney; Stephen Campbell; Johanna C Meyer
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.